Newly Cleared Genetic Test Will Allow Patient Targeting For Pfizer’s Camptosar
This article was originally published in The Pink Sheet Daily
Executive Summary
Third Wave’s Invader test will identify patients with two copies of the variant allele UGT1A1, which increases the risk of developing neutropenia while on irinotecan.